Stay updated on Resmetirom in NASH and Fibrosis Clinical Trial
Sign up to get notified when there's something new on the Resmetirom in NASH and Fibrosis Clinical Trial page.

Latest updates to the Resmetirom in NASH and Fibrosis Clinical Trial page
- CheckyesterdayChange DetectedThe government funding status notice and related topics (Non-alcoholic fatty liver disease and MedlinePlus Genetics) were removed from the page; core study details and navigation remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe page now includes related topics such as Non-alcoholic fatty liver disease and MedlinePlus Genetics, plus a new citation for a secondary analysis of MAESTRO-NASH (Noureddin et al., 2025). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check22 days agoChange DetectedRemoved the MeSH term 'Non-alcoholic fatty liver disease' and the related topic 'MedlinePlus Genetics' from the related terms on the study record. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check29 days agoChange DetectedRemoved a MedlinePlus Genetics topic: Non-alcoholic fatty liver disease, narrowing the range of covered topics.SummaryDifference0.2%

- Check37 days agoChange DetectedUpdated regional naming from Rhone-Alpes to Auvergne-Rhône-Alpes and adjusted the Lyon listing to reflect the current region designation.SummaryDifference4%

- Check44 days agoChange DetectedCore content updated to include government operating status notice and new version v3.2.0; prior version v3.0.2 removed.SummaryDifference2%

Stay in the know with updates to Resmetirom in NASH and Fibrosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Resmetirom in NASH and Fibrosis Clinical Trial page.